Skip to main content
Kindstar Globalgene Technology, Inc. logo

Kindstar Globalgene Technology, Inc. — Investor Relations & Filings

Ticker · 9960 ISIN · KYG5262E1044 HKEX Human health and social work activities
Open in API
Filings indexed 602 across all filing types
Latest filing 2024-09-26 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 9960

About Kindstar Globalgene Technology, Inc.

http://www.kindstar.com.cn

Kindstar Globalgene Technology, Inc. is a leading independent provider of advanced specialty clinical testing services, specializing in esoteric testing. The company maintains the largest esoteric testing portfolio in its market, utilizing internationally-advanced laboratory facilities for clinical testing, scientific research, and applied R&D. Its comprehensive testing menu, featuring over 100 items, covers critical diagnostic areas including hematology, genetic diseases, gynecology, infectious diseases, neurology, and oncology. These services provide physicians and patients access to specialized diagnostics crucial for the diagnosis and treatment of major diseases.

Recent filings

Filing Released Lang Actions
2024 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 Interim Report' and contains detailed sections such as Business Review and Outlook, Management Discussion and Analysis, Independent Review Report, and Interim Condensed Consolidated Financial Statements including Profit or Loss, Financial Position, Changes in Equity, Cash Flows, and Notes. The report covers the six months ended June 30, 2024, which is a period shorter than a full fiscal year. The content includes substantive financial data and analysis, consistent with an interim or quarterly financial report. The length of the document (15,000 characters) and the detailed financial and operational information confirm it is the actual interim report, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-09-26 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and details changes in issued shares and treasury shares, specifically a share repurchase by Kindstar Globalgene Technology, Inc. It references rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share repurchases and changes in issued shares. The content includes detailed tables of share counts before and after repurchase, repurchase prices, and confirmations of compliance with exchange rules. The document is 9594 characters long, which is substantial and contains detailed transactional data rather than a brief announcement. This matches the description of a Transaction in Own Shares (POS) filing, which reports on share buybacks or sales of treasury shares. It is not an announcement of a report, nor a general regulatory filing, but a detailed disclosure of share repurchase activity. Therefore, the correct classification is POS with high confidence.
2024-09-25 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and details changes in issued shares and treasury shares, specifically a repurchase of shares by Kindstar Globalgene Technology, Inc. It references compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and GEM Rules. The content includes detailed tables of share repurchases, prices, and confirmations related to share buybacks. This is a regulatory disclosure about share repurchase activity, not a full financial report or earnings release. It fits the description of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is not a brief announcement but a formal report of share repurchase activity.
2024-09-23 English
(1) DISCLOSEABLE TRANSACTION - ACQUISITION OF EQUITY INTEREST IN THE TARGET COMPANIES INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE&#x3b; AND (2) THE NEW TARGET CONTRACTUAL ARRANGEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kindstar Globalgene Technology, Inc. regarding a discloseable transaction involving the acquisition of equity interest in target companies and issuance of consideration shares. It details the transaction agreement, parties involved, consideration, and conditions precedent. The content focuses on a corporate transaction and financing activity, specifically an acquisition and issuance of shares under a general mandate. There is no indication that this is a full financial report, audit report, earnings release, or regulatory certification. The document is not a proxy solicitation, voting result, or management change announcement. It is a detailed announcement of a capital transaction involving share issuance and acquisition, fitting the Capital/Financing Update category. The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-09-20 English
VOLUNTARY ANNOUNCEMENT - PROPOSED ACQUISITIONS OF EQUITY INTERESTS IN THE TARGET COMPANIES
M&A Activity Classification · 95% confidence The document is a voluntary announcement by Kindstar Globalgene Technology, Inc. regarding proposed acquisitions of equity interests in target companies. It explicitly states that no legally binding transaction documents have been signed yet and that the acquisitions are expected to constitute a discloseable transaction under the Listing Rules. The document is an announcement of potential M&A activity, not a completed merger or acquisition filing, nor a detailed merger communication or proxy statement. It is not a full report or financial statement but an update on ongoing negotiations related to acquisitions. Therefore, the most appropriate classification is 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2024-09-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, and confirms no changes in warrants, convertibles, or other agreements. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables of share capital and share movements. The document is a regulatory monthly return about share capital and share movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a regulatory filing itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about share capital and securities movements that does not fit other specific categories like Share Issue/Capital Change (SHA) because it covers a monthly return format under exchange rules rather than a specific capital change event.
2024-09-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.